PrEP use among U.S. young adults has risen sharply since 2016, but declining treatment persistence—especially among those aged 18–21—raises concerns about long-term HIV prevention effectiveness.
Most Recent Articles
New Statin Therapy Guidelines for People with HIV Focus on Primary Prevention of Cardiovascular Disease
New U.S. guidelines recommend statins for people with HIV aged 40–75 with moderate cardiovascular risk, aiming to prevent heart disease based on REPRIEVE trial data showing a 36% reduction in events.
New Multidimensional Framework for Characterizing Traumatic Brain Injury Developed
A new NIH-backed framework combines clinical exams, biomarkers, imaging, and contextual factors to improve traumatic brain injury assessment. It aims to replace outdated severity labels with more individualized care strategies.
Combining Monoclonal Antibodies to Prevent Viral Escape Mutations in SARS-CoV-2 Treatment
Combining monoclonal antibodies that target different parts of the virus can prevent escape mutations in SARS-CoV-2, offering a more durable and effective treatment strategy against evolving variants.
Obicetrapib-Ezetimibe Combination Reduces LDL Cholesterol by Nearly 50% in Resistant Hypertension
A fixed-dose combination of obicetrapib and ezetimibe lowered LDL cholesterol by nearly 50% in high-risk patients on statins, offering a promising option for those with resistant hypercholesterolemia.